Rivaroxaban for the treatment of cerebral venous thrombosis

Rivaroxaban for the treatment of cerebral venous thrombosis

Abstract Background New Oral Anticoagulants (NOACs) such as Rivaroxaban are introduced as alternatives to conventional vitamin-K antagonists in the long-term treatment of thrombotic events due to their lower bleeding risk. There is a lack of evidence on the effectiveness and safety of Rivaroxaban in...

Full description

Bibliographic Details
Main Authors: Sara Esmaeili, Meysam Abolmaali, Sobhan Aarabi, Mohammad Reza Motamed, Samira Chaibakhsh, Mohammad Taghi Joghataei, Mohammad Mojtahed, Zahra Mirzaasgari
Format: Article
Language:English
Published: BMC 2021-02-01
Series:BMC Neurology
Subjects:
Cerebral venous thrombosis
Rivaroxaban
Warfarin
Recanalization
Bleeding risk
Online Access:https://doi.org/10.1186/s12883-021-02091-1

Internet

https://doi.org/10.1186/s12883-021-02091-1

Similar Items